Tofacitinib (Cas:477600-75-2)

Tofacitinib (Cas:477600-75-2)
Model:API-Tofacitinib
Brand:Huavet
Origin:Made In China
Category:Chemicals / Organic Chemical Materials / Pharmaceutical Chemicals
Label:Tofacitinib , 477600-75-2
Price: -
Min. Order:1 gram

Product Description

Product Name: Tofacitinib (CP-690550,Tasocitinib)

CAS No.: 477600-75-2

Information: Janus kinase inhibitor

Other Names: CP-690550;Tasocitinib

Chemical Name: 3-[(3R,4R)-4-methyl-3-[methyl(7H-pyrrolo[2,3-d]pyrimidin-4-yl)amino]piperidin-1-yl]-3-oxopropanenitrile

Canonical SMILES: CC1CCN(CC1N(C)C2=NC=NC3=C2C=CN3)C(=O)CC#N

MF: C16H20N6O

MW 312.3696

Purity: 98% min.

Appearance: White to light yellow powder

Grade Standard: Medicine Grade

Type: Medicine to cure rheumatism or arthritis

Model Number: API-Tofacitinib

Solubility: Soluble in DMSO > 10 mM 

Storage: Store at -20°C 

General tips: For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20 for several months. 

Shipping Condition: Evaluation sample solution: ship with blue ice. All other available size: ship with RT , or blue ice upon request

Background: Tofacitinib, also named CP-690550 orTasocitinib, is a novel oral Janus kinase inhibitor which is being used as a targeted immune-modulator. It primarily inhibits signaling through heterodimeric receptors associated with JAK3, JAK1, or both of them, with functional selectivity over JAK2-paired receptors. Inhibition of JAK1 and JAK3 by tofacitinib blocks signaling for several cytokines, including interleukins 2, 4, 7, 9, 15, and 21. These cytokines are integral to lymphocyte activation, function, and proliferation. Tofacitinib is also an inhibitor of STAT molecules. Recent efforts to investigate the mechanism of action have shown that tofacitinib interacts with multiple JAKs and presumably other kinases

References:

Roy Fleischmann, Joel Kremer, John Cush, Hendrik Schulze-Koops, Carol A. Connell, John D. Bradley, David Gruben, Gene V. Wallenstein, Samuel H. Zwillich, and Keith S. Kanik. Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis. N Engl J Med 2012; 367:495-507

William J. Sandborn, Subrata Ghosh, Julian Panes, Ivana Vranic, Chinyu Su, Samantha Rousell, Wojciech Niezychowski. Tofacitinib, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis. N Engl J Med 2012; 367:616-624.

Keisuke Maeshima, Kunihiro Yamaoka, Satoshi Kubo, Kazuhisa Nakano, Shigeru Iwata, Kazuyoshi Saito, Masanobu Ohishi, Hisaaki Miyahara, Shinya Tanaka, Koji Ishii, Hironobu Yoshimatsu, Yoshiya Tanaka. The JAK Inhibitor Tofacitinib Regulates Synovitis Through Inhibition of Interferon- and Interleukin-17 Production by Human CD4 T Cells. Arthritis & Rheumatism. 2012. 64(6): 1790–1798.

Brand Name: Huavet

Place of Origin: Shaanxi, China (Mainland)

Usage: Pharmaceutical Intermediates

Inventory status: in stock

Shelf life: 2 years

Sample: Available

COA (Certificate Of Analysis): Available

MSDS (Material Safety Data Sheet): Available

HPLC Spectrum: Available

ISO: Approved

GC: Available

NMR (Nuclear Magnetic Resonance): Available

Packaging Details: 1g,5g,10g,50g,100g/bottle, 1kg/tin for trial order,25kg/drum for commercial quantity. Specific packing required by customer

Delivery Detail: Prompt shipment

Tofacitinib (Cas:477600-75-2) 1

Member Information

Shaanxi Huavet Chemical Co.,Ltd.
Country/Region:Shaan Xi - China
Business Nature:Manufacturer
Phone:13891930268
Contact:Mr.Gordon Dong (Sales Manager)
Last Online:15 Dec, 2022